瑞格列奈联合二甲双胍治疗对2型糖尿病肥胖患者血糖及胰岛素早期分泌时相的影响

Influence of repaglinide combined with metformin on blood glucose and early phase of insulin secretion in obese patients with type 2 diabetes

目的 探讨瑞格列奈联合二甲双胍治疗对2型糖尿病肥胖患者血糖及胰岛素早期分泌时相的影响。方法 2013年1月~2015年1月,选择本院收治的初诊2型糖尿病肥胖患者84例,将患者随机分为研究组和对照组,每组42例。对照组给予瑞格列奈治疗,研究组给予瑞格列奈联合二甲双胍治疗,治疗1个月后,观察两组血糖、血胰岛素水平的变化情况。结果 两组治疗前的空腹血糖（FPG）、餐后血糖（0.5、2 h PG）、糖化血红蛋白（Hb A1c）水平差异无统计学意义（P〉0.05）,研究组治疗后的FPG、PG、Hb A1c水平均明显低于对照组（P〈0.05）;两组治疗前的空腹胰岛素（FINS）、餐后胰岛素（0.5、2 h PINS）水平差异无统计学意义（P〉0.05）,研究组治疗后的PINS明显高于对照组（P〈0.05）。结论 瑞格列奈联合二甲双胍治疗2型糖尿病肥胖患者能更有效地改善其血糖水平,促进餐后胰岛素分泌,改善胰岛素早期分泌时相,值得应用。

objective To explore the influence of repaglinide combined with metformin on blood glucose and Early phase of insulin secretion in obese patients with type 2 diabetes. Methods From January 2013 to January 2015,84 obese patients with type 2 diabetes treated in our hospital were selected and randomly divided into research group（n=42） and control group（n=42）. Control group was given repaglinide treatment,and research group was given repaglinide combined with metformin,after 1 month treatment,the change of blood glucose and insulin level in two groups were observed. Results Before treatment,the fasting plasma glucose（FPG）,postprandial glucose（0.5,2 h PG）,hemoglobin A 1c（Hb A1c） level between two groups were not significantly different（P〉0.05）,after treatment,FPG,PG,Hb A1 c level of research group was significantly lower than that of control group（P〈0.05）.Before treatment,the fasting insulin（FINS）,postprandial insulin（0.5 h, 2 h PINS） level between two groups were not significantly different（P〉0.05）,PINS in research group was significantly higher than that of control group（P〈0.05）. Conclusion Repaglinide combined with metformin in obese patients with type 2 diabetes can more effectively improve the blood glucose level,promote the postprandial insulin secretion,improve early phase of insulin secretion,and it is worthy of application.